by John Conrad | Sep 24, 2024 | Member News, NewsBrief
Swedish rare disease specialist Immedica Pharma AB continues to strengthen its position in the U.S. market with two significant announcements this month. Chicago Becomes U.S. Base for Global Rare Disease Company On September 9th, Immedica revealed plans to establish...
by John Conrad | Sep 23, 2024 | Member News
Chicago-based NanoGraf, a leader in advanced silicon anode battery technology, has been awarded a $60 million grant from the U.S. Department of Energy as part of the Bipartisan Infrastructure Law. This substantial funding will support the construction of one of the...
by John Conrad | Sep 19, 2024 | NewsBrief
Syntax Bio has launched with $15 million in funding from notable investors, including Astellas Venture Management LLC and Illumina Ventures. The Chicago-based startup is pioneering a novel approach to cell therapy with its Cellgorithm platform. Syntax Bio’s...
by John Conrad | Sep 19, 2024 | Member News
MAIA Biotechnology (NYSE American: MAIA) has announced encouraging interim survival data for its lead clinical candidate, THIO, in the treatment of advanced non-small cell lung cancer (NSCLC). The Chicago-based biopharmaceutical company is developing THIO as a...
by John Conrad | Sep 11, 2024 | NewsBrief
In a significant development for the healthcare industry, Chicago-based 32 Biosciences has announced its emergence from stealth mode, unveiling a groundbreaking approach to gut microbiome medicine. The company, whose name is pronounced “Three Squared...
by John Conrad | Sep 9, 2024 | NewsBrief
Immedica Pharma AB, a Stockholm-based pharmaceutical company specializing in rare and severe diseases, has announced its expansion into the United States market. The company has established Immedica Pharma US Inc., with headquarters in Chicago, marking a significant...
